| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
|---|---|
| ECF | effective capillary flow; eosinophilic chemotactic factor; erythroid colony formation; extended care... |
| ECU | environmental control unit; extended care unit; extensor carpi ulnaris |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| EHC | enterohepatic circulation; enterohepatic clearance; essential hypercholesterolemia; ethylhydrocuprei... |
| zinc sulfocarbolate | Used as an intestinal antiseptic and locally as an astringent in chronic inflammation of the mucous membranes. Synonym: zinc sulfocarbolate. (05 Mar 2000) |
|---|---|
| zinc superoxide | ZnO2;a yellowish white powder, insoluble in water and decomposed by acids; used in pharmaceutical preparations. Synonym: zinc superoxide. (05 Mar 2000) |
| zinc undecylenate | Zinc undecenoate, [CH2==CH(CH2)8COO]2Zn;the zinc salt of undecylenic acid; used in the treatment of fungal and other affections of the skin, including psoriasis. (05 Mar 2000) |
| zinc white | <chemical> A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock. Pharmacological action: dermatologic agents, sunscreening agents. Chemical name: Zinc oxide (ZnO) (12 Dec 1998) |
| unmodified zinc oxide-eugenol cement | A dental cement obtained by mixing zinc oxide and eugenol without modifiers. (05 Mar 2000) |
| flowers of zinc | <chemical> A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock. Pharmacological action: dermatologic agents, sunscreening agents. Chemical name: Zinc oxide (ZnO) (12 Dec 1998) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| regular insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| globin insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |